Results 51 to 60 of about 45,696 (262)

Presentation_1_Omic insights into various ceftazidime-avibactam-resistant Klebsiella pneumoniae isolates from two southern Italian regions.pptx

, 2023
Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria.
Nadia Marascio (3819316), Maria Lina Mezzatesta (6178598), Angela Quirino (3413834), Giuseppe G. M. Scarlata (14330373), Grete F. Privitera (14330370), Giovanni Matera (6114287), Dalida A. Bivona (14330364), Nicolò Musso (6101027), Stefania Stefani (188822), Carlo Torti (237805), Claudia Cicino (14330367), Dafne Bongiorno (14330361), Alessandro Russo (43423), Enrico M. Trecarichi (10017149)   +13 more
core   +1 more source

IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES

İstanbul Tıp Fakültesi Dergisi, 2022
Objective: Infections caused by multi drug-resistant Gram-negative bacilli are increasingly reported worldwide. Ceftazidime-avibactam is a novel antibiotic combination that presents good activity against carbapenem-resistant Enterobacterales members and ...
Tuğrul Hoşbul, Canset Nur Aydoğan, Sinem Kaya, Orhan Bedir, Hande Özcan, Ramazan Gümral   +5 more
doaj   +1 more source

An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance

Open Forum Infectious Diseases, 2023
Background Cefiderocol and ceftazidime-avibactam plus aztreonam (CZA-ATM) are preferred treatment regimens for New Delhi metallo-β-lactamase (NDM)-producing infections.
P. Simner, Y. Bergman, Rick Conzemius, E. Jacobs, Tsigereda Tekle, S. Beisken, P. Tamma   +6 more
semanticscholar   +1 more source

Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases. [PDF]

, 2020
Class D β-lactamases exhibit very heterogeneous hydrolysis activity spectra against the various types of clinically useful β-lactams. Similarly, and according to the available data, their sensitivities to inactivation by avibactam can vary by a factor of
Bouillenne, Fabrice, Joël Moray, Stefanic, Patrick, Alain Brans, Bogaerts, Pierre, Brans, Alain, Bogaerts, P., Huang, Te-Din, Huang, T.-D., Patrick Stefanic, Te-Din Huang, Moray, Joël, Frère, Jean-Marie, Pierre Bogaerts, Jean-Marie Frère, Fabrice Bouillenne   +15 more
core   +1 more source

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

International Journal of Infectious Diseases, 2017
Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom, Hashim Elsayed, Karen Lawlor, Laila AbdelWareth, Rania El-Lababidi, Lysettee Cardona, Mohammad Mooty, Maria-Fernanda Bonilla, Ahmad Nusair, Imran Mirza   +9 more
doaj   +1 more source

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria

Frontiers in Microbiology, 2022
Ceftazidime-avibactam is one of the last resort antimicrobial agents for the treatment of carbapenem-resistant, Gram-negative bacteria. Metallo-β-lactamase-producing bacteria are considered to be ceftazidime-avibactam resistant. Here, we evaluated a semi-
Michaela Simon, Michaela Simon, Roman G. Gerlach, Yvonne Pfeifer, Niels Pfennigwerth, Sören G. Gatermann, Agnes Schröder, Agnes Schröder, Andreas Hiergeist, Axel Hamprecht, Axel Hamprecht, Axel Hamprecht, Axel Hamprecht, Tamara Rügamer, André Gessner, Jonathan Jantsch, Jonathan Jantsch   +16 more
doaj   +1 more source

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope

Annals of Clinical Microbiology and Antimicrobials, 2023
Background Carbapenemase-producing Enterobacterales (CPE) show rapid global dissemination and pose a significant therapeutic challenge. This study aimed to characterize carbapenemase-producing Klebsiella spp. and Escherichia coli ( E.
Rawan Taha, O. Kader, S. Shawky, Shahinda Rezk   +3 more
semanticscholar   +1 more source

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam

WIREs Mechanisms of Disease, 2022
AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal
Luying Xiong, Xueting Wang, Yuan Wang, Wei Yu, Yanzi Zhou, Xiaohui Chi, Tingting Xiao, Yonghong Xiao   +7 more
openaire   +2 more sources

A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring bla_KPC-14 Isolated in New York City

mSphere, 2020
Ceftazidime-avibactam is a potent antibiotic combination against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. Here, we describe a unique ceftazidime-avibactam-resistant and carbapenem-susceptible K.
Siqiang Niu, Kalyan D. Chavda, Jie Wei, Chunhong Zou, Steven H. Marshall, Puneet Dhawan, Deqiang Wang, Robert A. Bonomo, Barry N. Kreiswirth, Liang Chen   +9 more
doaj   +3 more sources

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019

Brazilian Journal of Infectious Diseases, 2021
The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to
James A. Karlowsky, Krystyna M. Kazmierczak, Maria Lavínea Novis de Figueiredo Valente, Elkin Lemos Luengas, Monique Baudrit, Alvaro Quintana, Paurus Irani, Gregory G. Stone, Daniel F. Sahm   +8 more
doaj   +1 more source